Search
Mepenzolate
go.drugbank.com/drugs/DB04843ApprovedWithdrawnIt has not been shown to be effective in contributing to the healing of peptic ulcer, decreasing the rate of recurrence, or preventing complications. … Pharmacologically, it is a post-ganglionic parasympathetic inhibitor.
Thyroglobulin
go.drugbank.com/drugs/DB01584ApprovedWithdrawnThyroglobulin (also known as Tg) is an enzyme thyroid hormone used by the thyroid gland to produce the thyroid hormones thyroxine (T4) and triiodothyronine (T3).
Vibegron
go.drugbank.com/drugs/DB14895ApprovedInvestigationalOn December 23, 2020, vibegron was approved for the same indication in adults. It is available as oral tablets under the market name GEMTESA. … Unlike mirabegron, vibegron is less likely to be associated with drug-drug interactions involving the CYP3A4, 2D6, or 2C9 enzymes.[A226065]
Smallpox (Vaccinia) Vaccine, Live
go.drugbank.com/drugs/DB14711ApprovedInvestigational[L12747] ACAM2000, a percutaneously administered smallpox vaccine that was approved by the FDA in 2007, contains live antigens of this strain.
NOX-700
go.drugbank.com/drugs/DB05464ExperimentalIn animal studies, NOX-700 lowered serum glucose, improved glucose tolerance, and reduced the percentage of total glycated hemoglobin. … NOX-700, an new orally active dithiocarbamate-based nitric oxide (NO) blocking agent that is in development for the treatment of diabetes mellitus (type 2 diabetes).
Tirbanibulin
go.drugbank.com/drugs/DB06137ApprovedInvestigational[A225726] On December 14, 2020, tirbanibulin was approved by the FDA for the topical treatment of actinic keratosis on the face or scalp. It is marketed under the brand name Klisyri. … [L27806] Actinic keratosis is a chronic condition characterized by lesions, which can potentially transform into invasive squamous cell carcinoma with a risk of 1% over 10 years.
Temoporfin
go.drugbank.com/drugs/DB11630ApprovedIt was first authorized for market by the European Medicines Agency in October 2001. It is currently available under the brand name Foscan.
Synonyms: m-THPC, 2,3-dihydro-5,10,15,20-tetra(m-hydroxyphenyl)porphyrinLG-100268
go.drugbank.com/drugs/DB01941ExperimentalLG-100268 is a retinoid X receptor (RXR) selective compound.
Crizanlizumab
go.drugbank.com/drugs/DB15271ApprovedInvestigational[L10097] While crizanlizumab received conditional marketing authorization from the EMA in October 2020, this approval was revoked in August 2023 due to concerns over the efficacy and safety of the drug … It was developed by Novartis and was granted FDA approval on November 15, 2019.
Categories: Immunoglobulin G